Early signs Alto’s precision neuropsychiatry approach may be working

With its third positive Phase IIa result this year, Alto is off to a strong start in its quest to demonstrate the power of biomarker-driven patient selection to improve success rates in neuropsychiatry. A series of four more Phase II readouts over the next two years will shed additional light on whether the company is proving out its thesis.

On Monday, Los Altos, Calif.-based Alto Neuroscience Inc. announced that an electroencephalogram (EEG)-based biomarker it created, with the help of machine learning, successfully enriched for responders to pipeline candidate ALTO-300 in a Phase IIa study. ...